April 28, 2025 01:48 PM EDTUpdated 03:35 PM

Novavax responds to FDA’s trial ask, with Covid vaccine strain updates under scrutiny

Max Bayer

Pharma Reporter

Novavax said it’s responded to the FDA’s request for a new clinical trial post-approval of the company’s Covid-19 vaccine, following a report that the agency …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novavax responds to FDA’s trial ask, with Covid vaccine strain updates under scrutiny

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Boehringer’s updated results in HER2-mutated lung cancer impress

Scholar Rock names new CEO, adds biotech veterans in C-suite rebuild

Merck KGaA to buy rare cancer biotech SpringWorks for $3.9B

GSK’s checkpoint blocker Jemperli cures biomarker-driven rectal cancer

Exclusive: Can AI replace animal testing? A new biotech launches to find out

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

No­vavax re­sponds to FDA’s tri­al ask, with Covid vac­cine strain up­dates un­der scruti­ny

Pharma Reporter

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Novavax responds to FDA’s trial ask, with Covid vaccine strain updates under scrutiny